Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Medikaloka Hermina Tbk Other Financing Calculation
Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges
Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp855,683 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Financing of Rp855,683 Mil mean?
PT Medikaloka Hermina Tbk (ISX:HEAL) has a Other Financing of Rp855,683 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for PT Medikaloka Hermina Tbk and its competitors.
Is PT Medikaloka Hermina Tbk's Other Financing too high?
PT Medikaloka Hermina Tbk's current Other Financing is Rp855,683 Mil. Overall, PT Medikaloka Hermina Tbk has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Medikaloka Hermina Tbk's Other Financing compare to HCA and THC?
PT Medikaloka Hermina Tbk's Other Financing of Rp855,683 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Healthcare Providers & Services company?
A good Other Financing depends on the Healthcare Providers & Services industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for PT Medikaloka Hermina Tbk and its competitors. PT Medikaloka Hermina Tbk's current Other Financing is Rp855,683 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Medikaloka Hermina Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Medikaloka Hermina Tbk (ISX:HEAL) is currently considered Significantly Undervalued. The stock's GF Value™ is Rp1,586.45, compared to a current price of Rp775.00 — trading 51.1% below its estimated fair value. The current Other Financing is Rp855,683 Mil. PT Medikaloka Hermina Tbk's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For PT Medikaloka Hermina Tbk (ISX:HEAL), the current Other Financing is Rp855,683 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Medikaloka Hermina Tbk (ISX:HEAL) Overvalued in 2026?
Based on GuruFocus' analysis, PT Medikaloka Hermina Tbk stock appears to be undervalued.
The current stock price of Rp775.00 is trading 51.1% below its estimated GF Value™ of Rp1,586.45.
GuruFocus considers PT Medikaloka Hermina Tbk to be Significantly Undervalued.
Key valuation signals for ISX:HEAL:
Other Financing: Rp855,683 Mil
GF Value™: Rp1,586.45 vs. price of Rp775.00 (51.1% below fair value)
No single metric tells the full story. See the ISX:HEAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Medikaloka Hermina Tbk is a private hospital group. It provides a range of medical services, including maternal and child health services, complex operating procedures, laboratory services, radiology facilities, and fertility treatments as well as general health services, pharmacies, diagnostic and emergency services. The company's geographical segment includes Kalimantan dan Sulawesi, Jawa, and Sumatera. It derives maximum revenue from the Jawa segment.
67GF Score
Get the complete analysis for ISX:HEAL
Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:HEAL has been successfully added to your 
